Blueprint Medicines (BPMC) Scheduled to Post Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) will be issuing its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.65) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts' consensus estimates of ($2.04) by $0.22. The firm had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The company's revenue was up 85.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.65) EPS. On average, analysts expect Blueprint Medicines to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Blueprint Medicines Stock Performance

Blueprint Medicines stock traded down $0.03 during mid-day trading on Wednesday, reaching $92.26. 588,540 shares of the company's stock were exchanged, compared to its average volume of 764,526. The business's fifty day simple moving average is $90.67 and its 200 day simple moving average is $78.42. The company has a quick ratio of 3.66, a current ratio of 3.76 and a debt-to-equity ratio of 1.60. Blueprint Medicines has a one year low of $43.89 and a one year high of $101.00. The firm has a market capitalization of $5.65 billion, a PE ratio of -11.04 and a beta of 0.63.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Barclays boosted their target price on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 13th. Wedbush reiterated an "outperform" rating and set a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 5th. JMP Securities reiterated a "market outperform" rating and set a $114.00 price target on shares of Blueprint Medicines in a research note on Wednesday, April 10th. Citigroup increased their price target on Blueprint Medicines from $54.00 to $65.00 and gave the stock a "sell" rating in a research note on Friday, February 16th. Finally, Stifel Nicolaus increased their price target on Blueprint Medicines from $95.00 to $97.00 and gave the stock a "buy" rating in a research note on Tuesday, January 9th. Four analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $85.43.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, EVP Tracey L. Mccain sold 5,194 shares of the firm's stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $471,043.86. Following the sale, the executive vice president now owns 60,498 shares of the company's stock, valued at approximately $5,486,563.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Christopher K. Murray sold 621 shares of the firm's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now directly owns 36,374 shares of the company's stock, valued at approximately $3,406,425.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Tracey L. Mccain sold 5,194 shares of the firm's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $471,043.86. Following the transaction, the executive vice president now directly owns 60,498 shares in the company, valued at $5,486,563.62. The disclosure for this sale can be found here. Insiders have sold a total of 117,289 shares of company stock valued at $10,361,913 in the last 90 days. Corporate insiders own 3.88% of the company's stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.